Diphtheria: Why a vaccine-preventable disease still spreads

Four confirmed cases of diphtheria have been identified in the southern region of Cameroon, prompting the Ministry of Public Health to mobilize 18,000 vaccine doses in a rapid response effort. This specific incident highlights a critical reality in global health: despite the existence of highly effective vaccines, diphtheria is far from eradicated. It remains a persistent threat in specific geographic pockets where immunity gaps, migration patterns, and surveillance challenges intersect.

The question of why diphtheria persists, often referred to in French contexts as diphtérie, is not a simple one. It is not merely a failure of vaccine development but a complex interplay of immunological waning, population mobility, and uneven access to routine immunization programs. In Europe, the World Health Organization reports that while the region has averted further backsliding in routine immunization, it still falls short of full recovery. This stagnation creates a fragile shield against the reintroduction of the bacterium Corynebacterium diphtheriae, particularly in vulnerable populations such as migrants and the elderly.

Understanding the current incidence rates requires looking beyond isolated outbreaks to the structural factors that allow the disease to survive. The persistence of diphtheria in certain regions is a testament to the limitations of herd immunity when coverage is incomplete or when immunity wanes over time. As we examine the data from Cameroon, Europe, and the broader global landscape, a clearer picture emerges of why this ancient disease continues to claim attention and resources in 2026.

The Cameroon Outbreak: A Case Study in Rapid Response

The situation in Cameroon provides a stark example of how diphtheria can resurface in regions with historically high vaccination coverage. According to reports from Le National, the Ministry of Public Health responded swiftly to the four confirmed cases by deploying 18,000 vaccine doses. This large-scale mobilization underscores the severity of the threat and the immediate need to close immunity gaps in the affected southern districts.

What makes this outbreak particularly noteworthy is the speed of the response. In a region where healthcare infrastructure can be strained, the ability to mobilize and distribute vaccines so quickly is a testament to the preparedness of local health authorities. However, it also raises questions about why the disease was able to take hold in the first place. Did routine immunization coverage dip below the threshold needed for herd immunity? Were there pockets of unvaccinated children or adults whose immunity had waned?

The Cameroon case is not an isolated incident but part of a broader pattern of diphtheria resurgence in parts of Africa and Asia. It serves as a reminder that even in regions where the disease has been largely controlled, vigilance is essential. The rapid response in Cameroon is a positive step, but it is also a signal that the disease is still circulating in the region, waiting for the next opportunity to exploit a gap in immunity.

Europe's Immunity Gap and the Migrant Factor

In Europe, the picture is more nuanced but equally concerning. The World Health Organization’s European Region report indicates that while routine immunization rates have stabilized, they have not fully recovered to pre-pandemic levels. This plateau in vaccination coverage creates a vulnerable window where diphtheria can re-emerge. A recent study published in the New England Journal of Medicine highlights an outbreak of Corynebacterium diphtheriae specifically within migrant populations in Europe, drawing attention to how global mobility can intersect with local immunity gaps.

Migrant communities often face barriers to accessing routine healthcare, including language differences, cultural misunderstandings, and administrative hurdles. These barriers can lead to lower vaccination rates, creating clusters of individuals with waning or absent immunity. When an outbreak occurs in such a community, it can spread rapidly before public health authorities are even aware of its existence. The NEJM study underscores the importance of targeted surveillance and outreach programs in these populations to prevent the disease from spilling over into the wider community.

The European Centre for Disease Prevention and Control continues to monitor diphtheria cases across the continent, issuing updates on epidemiological trends. Their data suggests that while the number of cases remains low compared to historical peaks, the disease is far from gone. The persistence of diphtheria in Europe is a reminder that herd immunity is not a static state but a dynamic one that requires constant reinforcement through vaccination and public health vigilance.

Waning Immunity and the Challenge of Adult Vaccination

One of the most significant factors in the persistence of diphtheria is the waning of immunity over time. While childhood vaccination programs have been largely successful in preventing the disease in young children, adults who received their vaccines decades ago may have lost sufficient protection. This is particularly true in regions where booster shots are not routinely administered or where individuals do not have access to regular healthcare check-ups.

In France, for example, public health initiatives are increasingly focused on reminding adults of the need for booster vaccines against diphtheria, tetanus, and polio. A recent article in the Vinci Autoroutes radio network highlights the importance of keeping up to date with vaccinations, especially for seniors whose immune systems are naturally weakened by age. The article notes that while the vaccines are safe and effective, many adults are unaware that they need a booster or simply forget to get one.

This gap in adult vaccination coverage is a major vulnerability. Diphtheria is not just a childhood disease; it can affect individuals of any age. By focusing exclusively on childhood vaccination, public health systems may be overlooking a significant portion of the population that is at risk. Addressing this gap requires a shift in public health messaging to emphasize the lifelong nature of diphtheria protection and the importance of regular booster shots.

The Role of Surveillance and Genomic Tracking

Modern surveillance techniques are playing an increasingly important role in tracking diphtheria outbreaks and understanding how the disease is spreading. Whole genome sequencing, for instance, allows researchers to identify the specific strain of Corynebacterium diphtheriae involved in an outbreak and trace its origin. This technology has been used in Europe to monitor low incidence settings, providing valuable data on the genetic diversity of the bacterium and its potential for virulence.

The use of genomic tracking has proven particularly useful in identifying links between seemingly unrelated cases. By analyzing the genetic code of the bacterium, researchers can determine whether multiple cases stem from a common source or if they represent separate introductions of the disease. This information is crucial for guiding public health interventions and allocating resources effectively.

As diphtheria continues to persist in certain regions, the need for robust surveillance systems becomes even more critical. By combining traditional epidemiological methods with modern genomic tools, public health authorities can gain a more comprehensive understanding of the disease and respond more effectively to outbreaks. This integrated approach is essential for preventing the spread of diphtheria and protecting vulnerable populations.

The Path Forward: Strengthening Global Vaccination Efforts

The persistence of diphtheria in 2026 is a call to action for the global health community. It is a reminder that while we have made significant progress in controlling the disease, there is still much work to be done. This requires a multi-faceted approach that includes improving vaccination coverage, addressing barriers to access, and strengthening surveillance systems.

The Gates Foundation’s commitment of $1.6 billion to the Gavi vaccine alliance is a significant step in this direction. This funding will help support vaccination programs in low-income countries, where diphtheria remains a significant threat. By investing in the infrastructure and resources needed to deliver vaccines to remote and underserved areas, the Gavi alliance is helping to close the immunity gaps that allow the disease to persist.

However, funding alone is not enough. It requires a sustained commitment from governments, healthcare providers, and the public to prioritize vaccination and public health education. By working together, we can build a more resilient global health system that is better equipped to prevent and respond to diphtheria outbreaks. The persistence of the disease is a challenge, but it is also an opportunity to strengthen our collective efforts to protect human health.